Hybrid Core-Shell Nanoparticles for Enhanced Systemic mRNA Delivery

Study Background and Research Question

Messenger RNA (mRNA) therapeutics have gained significant attention due to their success in recent vaccine development and their versatility for gene editing, immunotherapy, and protein replacement strategies. Unlike DNA therapeutics, mRNA acts in the cytoplasm and avoids the risks associated with genomic integration. However, systemic delivery of mRNA and the efficient, targeted expression of encoded proteins remain major challenges, especially outside of prophylactic vaccination contexts (paper). This study addresses the critical question: Can engineering the surface properties of liposome-mRNA complexes with hyaluronic acid (HA) enhance delivery efficiency, biodistribution, and translation of mRNA in relevant immune cell populations?

Key Innovation from the Reference Study

The reference paper introduces a novel hybrid core-shell nanoparticle platform by electrostatically attaching hyaluronic acid to cationic liposome–mRNA complexes, forming hybrid liposome–RNA complexes (HLRCs). This surface modification transitions the nanoparticle's surface charge from positive to negative, a key parameter for both stability in circulation and interaction with biological barriers (paper). The approach leverages the biocompatibility and immune cell targeting properties of HA, combined with the high mRNA payload capacity and transfection efficiency of liposomal carriers.

Methods and Experimental Design Insights

The researchers systematically compared two nanoparticle systems:

• Liposome–RNA complexes (LRCs): Cationic liposomes complexed with in vitro transcribed (IVT) mRNA.
• Hybrid LRCs (HLRCs): LRCs further coated with hyaluronic acid, forming a core-shell architecture.

Physicochemical characterization included assessment of particle size (~200 nm), surface charge (zeta potential), and mRNA binding capacity. Cellular uptake and transfection efficiency were evaluated in vitro using THP-1 cells and primary human monocyte-derived cells. For in vivo studies, the team utilized radiolabeling and bioluminescence imaging to track biodistribution and protein translation sites following systemic administration in mice. The mRNA cargo encoded luciferase or enhanced green fluorescent protein (EGFP), enabling quantitative and spatial mapping of translation efficiency (paper).

Protocol Parameters

• particle size | ~200 nm | in vivo mRNA delivery | ensures prolonged circulation and tissue penetration | paper
• surface charge (zeta potential) | negative (post-HA coating) | systemic administration | reduces non-specific uptake and enhances immune targeting | paper
• mRNA payload | high binding capacity | gene expression studies | enables delivery of sufficient mRNA for detectable protein output | paper
• cell model | THP-1, human monocytes | ex vivo translation efficiency assay | relevant for immunotherapy and vaccine research | paper
• in vivo imaging | luciferase/EGFP reporter mRNA | translation site mapping | allows direct visualization of protein expression | paper
• recommended mRNA integrity | RIN > 8 | general mRNA delivery | high-quality mRNA improves translation efficiency and reproducibility | workflow_recommendation

Core Findings and Why They Matter

Both LRCs and HLRCs demonstrated high transfection efficiency in vitro, with effective delivery and translation of mRNA in monocyte-derived immune cells. The HA shell conferred a negative surface charge, which is advantageous for systemic stability and may reduce off-target interactions. In murine models, radiolabeling and bioluminescence imaging revealed that both particle types predominantly accumulated in the hepatic reticuloendothelial system (RES), but functional protein expression was primarily detected in the spleen—particularly within macrophages (paper). This highlights the importance of surface engineering not just for biodistribution, but also for ensuring that mRNA reaches and is translated in the desired immune cell populations.

Importantly, the study demonstrates that tailoring the surface properties of mRNA nanoparticles—such as charge and polymer coating—can fine-tune both the pharmacokinetic profile and cellular specificity of mRNA therapeutics. This is critical for developing next-generation mRNA platforms for applications such as cancer immunotherapy, where selective immune cell targeting and robust protein expression are required.

Comparison with Existing Internal Articles

Several internal articles provide complementary perspectives and technical insights on synthetic mRNA optimization and delivery workflows:

• "EZ Cap EGFP mRNA 5-moUTP: Next-Gen Capped mRNA for Advanced Assays" dives into how Cap 1 structures and 5-methoxyuridine modifications enhance mRNA stability and translation, which synergizes with delivery technologies such as those described in the reference study.
• "EZ Cap EGFP mRNA 5-moUTP: Enhanced Reporter Assays & Delivery" details troubleshooting and workflow optimization for gene expression and translation efficiency assays, supporting the practical application of hybrid nanoparticle delivery systems for in vitro and in vivo research.
• "EZ Cap™ EGFP mRNA (5-moUTP): Mechanistic Insights and Next Steps" explores immunomodulatory aspects and the impact of mRNA modifications on immune evasion, which are relevant for suppressing RNA-mediated innate immune activation during systemic delivery.

These resources, while focused on mRNA design and assay implementation, align with the reference study’s emphasis on delivery platform optimization and translation efficiency.

Limitations and Transferability

Although the HA-coated hybrid nanoparticles enhanced in vitro and in vivo translation in immune cells, the observed biodistribution favored hepatic and splenic uptake, which may limit applications requiring extrahepatic or tissue-specific delivery (paper). The translation of these findings to human clinical settings will require further investigation into nanoparticle scalability, immunogenicity, and functional targeting in diverse cell types. Additionally, the use of radiolabeled and bioluminescent reporter mRNAs, while powerful for mechanistic studies, may not fully predict performance with therapeutic or highly immunogenic mRNA payloads.

Why this cross-domain matters, maturity, and limitations

The application of hybrid nanoparticle engineering, originally advanced for infectious disease vaccines, into the realm of cancer immunotherapy and gene editing, holds promise for expanding the reach of mRNA-based treatments. However, as the reference study indicates, tailoring surface chemistry and charge must be rigorously matched to the cellular and tissue targets of interest. While the current work demonstrates proof-of-principle in immune cell targeting, further research is necessary to adapt these platforms for broader therapeutic targets and to validate them in human models (paper).

Research Support Resources

For researchers aiming to replicate or extend these workflows, high-quality reporter mRNAs are essential. EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016, APExBIO) offers a robust and well-characterized platform for translation efficiency assays, mRNA delivery studies, and in vivo imaging with fluorescent mRNA, incorporating Cap 1 structure and 5-methoxyuridine modifications to enhance stability and minimize innate immune activation (source: product_spec). Combined with hybrid core-shell nanoparticle systems, this reagent can facilitate reproducible evaluation of mRNA delivery and expression in complex biological models.